Timothy Scott

Mr. Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on lysosomal storage disorder and recombinant heparan sulfates. He previously was founder and President of Pharmatek Laboratories, a contract development and manufacturing company (sold to Catalent Pharma Solutions in 2016). Prior to that, he was Senior Vice President at Active.com (IPO 2011). Mr. Scott serves on the Board of Avelas, a bioscience company working to create better outcomes for cancer patients with its activatable cell-penetrating peptide technology. He previously served on the board of Zacharon Pharmaceuticals (sold to Biomarin 2014).

Mr. Scott is a member of the boards of BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California and CONNECT, a non-profit helping to create and scale innovation companies in San Diego. At UC San Diego, he serves on the Dean's Advisory Council for the Division of Biological Sciences. In the community, Mr. Scott serves on the board of the San Diego Blood Bank, and as a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.